I have just finished reading into Qbotics product, EBC-46. I am no expert however and just want state what I have understood from reading and listening to their media.
Seems this tech is also based on an "immune" response from the body, although somewhat more targeted via direct injection to a solid tumor.
It is interesting that this "immune" response technology is somewhat "fashionable" in terms of cancer therapies and have reduced or non-existant side-affects on the body. A huge plus when it comes to clinical testing I would say. Now it has passed FDA approval in USA via DNDN so its no joke and a serious advance.
So, I see this as a similar avenue to PRR in terms of immunotherapies, however PRR is well advanced to nearly starting the final stage 3. QBiotics have not yet started human testing. One can only speculate at this early although significant stage. I agree there is "no concern here" in terms of investing in PRR.
It is interesting QBiotics are open about wanting to sell their company to a major after stage 2 human testing results are complete.
QBiotics MC will be 50-60mil after the current cap raising which is before embarking on human testing, so are well priced relative to PRR, or PRR are well undervalued, so I suspect PRR could be re-rated on this news. This is good news for PRR.
PRR Price at posting:
13.5¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)